Global Seasonal Affective Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Disorder Type (Unipolar Disorder and Bipolar Disorder), By Treatment Type (Medications, Light Therapy, and Others) and Forecast, 2020-2026.
The global seasonal affective disorder therapeutics market is estimated to grow significantly during the forecast period. Rising demand for light therapy is one of the major factors driving the market growth. Light therapy, also referred to as phototherapy, is a treatment in which the person is exposed to an artificial light source. Light therapy is intended to primarily treat the seasonal affective disorder, a kind of depression that occurs for a certain time of year, normally winter. It is also utilized for the treatment of other conditions, such as sleep disorders and other forms of depression. The therapy is non-invasive, convenient, safe, and have few or mild side effects. All light therapy boxes for seasonal affective disorder treatment are designed to do the same thing, however, it differs based on effectiveness. Several companies are offering lightboxes for the treatment of the condition. This includes Koninklijke Philips N.V., Active Wearables GmbH, and Shine-Mart Ltd. (Duronic).
Geographically, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). Asia-Pacific is estimated to witness potential growth during the forecast period. The major factors contributing to the market growth in the region including the government initiatives for accessibility of mental condition treatment and emerging focus on insurance coverage for mental health. For instance, in India, According to Sec 21(4) of the Mental Healthcare Act, 2017, the Insurance Regulatory and Development Authority of India (IRDAI) has directed the insurers to offer medical insurance to cover mental illness treatments. This is expected to offer an opportunity for the adoption of seasonal affective disorder treatment in the country.
Some crucial players in the market include Otsuka Pharmaceutical Co., Ltd., AbbVie, Inc., Pfizer Inc., Koninklijke Philips N.V., and Active Wearables GmbH. Mergers and acquisitions, product launches, and partnerships and collaborations are considered as crucial strategies adopted by the market players to expand market share. For instance, in May 2019, Allergan plc and Gedeon Richter Plc. declared that the US FDA approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use for the treatment of depressive episodes related to bipolar I disorder in adults. This drug is also approved in the US for the treatment of manic or mixed episodes related to bipolar I disorder in adults. This new drug will support the treatment of bipolar depression in US adults.
Research Methodology
The market study of the global seasonal affective disorder therapeutics market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
1. Global Seasonal Affective Disorder Therapeutics Market Research and Analysis by Disorder Type
2. Global Seasonal Affective Disorder Therapeutics Market Research and Analysis by Treatment Type
The Report Covers
The global seasonal affective disorder therapeutics market is estimated to grow significantly during the forecast period. Rising demand for light therapy is one of the major factors driving the market growth. Light therapy, also referred to as phototherapy, is a treatment in which the person is exposed to an artificial light source. Light therapy is intended to primarily treat the seasonal affective disorder, a kind of depression that occurs for a certain time of year, normally winter. It is also utilized for the treatment of other conditions, such as sleep disorders and other forms of depression. The therapy is non-invasive, convenient, safe, and have few or mild side effects. All light therapy boxes for seasonal affective disorder treatment are designed to do the same thing, however, it differs based on effectiveness. Several companies are offering lightboxes for the treatment of the condition. This includes Koninklijke Philips N.V., Active Wearables GmbH, and Shine-Mart Ltd. (Duronic).
Geographically, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). Asia-Pacific is estimated to witness potential growth during the forecast period. The major factors contributing to the market growth in the region including the government initiatives for accessibility of mental condition treatment and emerging focus on insurance coverage for mental health. For instance, in India, According to Sec 21(4) of the Mental Healthcare Act, 2017, the Insurance Regulatory and Development Authority of India (IRDAI) has directed the insurers to offer medical insurance to cover mental illness treatments. This is expected to offer an opportunity for the adoption of seasonal affective disorder treatment in the country.
Some crucial players in the market include Otsuka Pharmaceutical Co., Ltd., AbbVie, Inc., Pfizer Inc., Koninklijke Philips N.V., and Active Wearables GmbH. Mergers and acquisitions, product launches, and partnerships and collaborations are considered as crucial strategies adopted by the market players to expand market share. For instance, in May 2019, Allergan plc and Gedeon Richter Plc. declared that the US FDA approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use for the treatment of depressive episodes related to bipolar I disorder in adults. This drug is also approved in the US for the treatment of manic or mixed episodes related to bipolar I disorder in adults. This new drug will support the treatment of bipolar depression in US adults.
Research Methodology
The market study of the global seasonal affective disorder therapeutics market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
1. Global Seasonal Affective Disorder Therapeutics Market Research and Analysis by Disorder Type
2. Global Seasonal Affective Disorder Therapeutics Market Research and Analysis by Treatment Type
The Report Covers
- Comprehensive research methodology of the global seasonal affective disorder therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global seasonal affective disorder therapeutics market.
- Insights about market determinants, which are stimulating the global seasonal affective disorder therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Active Wearables GmbH
- Aura Day Light
- Bristol-Myers Squibb Co.
- Carex Health Brands
- Eli Lilly & Co.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- H. Lundbeck A/S
- Koninklijke Philips N.V.
- Lucimed SA
- Mylan N.V.
- Novalogy, Inc.
- Novartis International AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Shine-Mart Ltd. (Duronic)
- Teva Pharmaceutical Industries Ltd.
- Verilux, Inc.
